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Serum-free culture conditions for the genera-
tion of dendritic cells from cord blood CD34+
hematopoietic progenitors: phenotypic and
functional analysis
Increasing pre-clinical and clinical data suggest
the efficiency of dendritic cells (DCs) in cancer
immunotherapy. Relapse after cord blood hemato-
poietic progenitors (CBHP) transplantation is an
unresolved problem. DCs obtained from CBHP
could be an interesting tool for relapse treatments,
but the low number of CBHP hinder their use for
DC generation.
Sir,
Umbilical cord blood (UCB) has been shown to be
an important alternative source of hematopoietic
progenitors for unrelated transplants in the treatment
of hematopoietic malignancies.1 Using this trans-
plantation modality, a lower incidence of graft-ver-
sus-host disease (GvHD) has been described, but pos-
sibly this is accompanied by a lesser graft-versus-
leukemia effect. Current results have shown that there
are still significant percentages of relapses and post-
transplant immunodeficiency-related deaths.2-4 Den-
dritic cells (DCs) are potent hematopoietic progeni-
tor-derived antigen presenting cells, which could be
used in specific immunotherapy by activating T-lym-
phocytes.5 However, the low number of HP in a unit
of UCB hampers the possibility of producing DCs
from the same transplant donor UCB unit.
This study shows that a limited number of UCB
hematopoietic progenitors can generate sufficient
quantities of active mature DCs under serum-free con-
ditions for use in immunotherapeutic treatment. We
optimized a combination of cytokines, containing:
SCF (50 ng/mL), Flt3-L (100 ng/mL), GM-CSF (50
ng/mL), TNF-α (3 ng/mL), TGF-b1 (0.5 ng/mL), and
compared this combination with a control containing
10% FBS. After 14 days of culture in the serum-free
medium, 105 CD34+ cells produced 1x107 ± 3.7x106
CD1a+ cells, which represented 43±16% of the total
cells in culture vs 1.29±1x107 (39±5.5%) in 10% FCS
containing medium (Figure 1). The CD1a+ cells gen-
erated in serum-free medium presented the following
phenotype: CD14- (46.5%), CD80 (94%), CD86
(88%), CD40 (99%), HLA-DR (99%), HLA-ABC
(100%) and CD83 (62%). Functionality was tested by
endocytic activity (approximately 27% of CD1a cells
label for FITC-dextran at day 10) and allogeneic T-
cell stimulation at day 14 [3 fold higher (75000 cpm
vs 25,000 cpm) than the CB CD34– fraction as a con-
trol]. 
TGF-β, one of the components of the cytokine
combination is a recognized inhibitor of multiple
immunologic functions (i.e., T-cell activities6 and pro-
motes a shift towards a Th2 phenotype7) and, there-
fore, DCs obtained in presence of TGF-β, prior to T-
cell activation, require the change to a TGF-β-free
medium. 
These cytokine combinations have also been test-
ed for the generation of DCs from adult sources of
hematopoietic progenitors. Functional characteris-
tics of these DCs are similar to those obtained from
UCB hematopoetic progenitors (data not shown),
however, as described for other myeloid lineages, the
expansion potential of adult hematopoetic progeni-
tors is lower.
The results obtained with this optimized cytokine
combination are comparable with those achieved
with 10% FCS instead of TGF-β.1 A schedule of DC for
patient vaccination has not yet been established, but
≈5 x105 to 107 DCs/ infusion has been used several
times in clinical trials, and clinical responses have
been reported.8-10 Our results show that expansion
of a small fraction of UCB hematopoietic progenitors
can produce sufficient quantities of DCs for immuno-
logical treatments.
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Figure 1. Percentage and number of CD1a+ cells obtained
at the indicated times of culture with the following cytokine
combination (B): recombinant human SCF (50 ng/mL), Flt-
3L (100 ng/mL), GM-CSF (50 ng/mL), TNF-a (3 ng/mL)
and alternatively TGF-b1 (0.5 ng/mL) (T) or 10% fetal calf
serum (positive control) (C).
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Single tube melting temperature assay for rapid
and sensitive detection of the most frequent
hemocromatosis mutations, C282Y and H63D
We report the development of a single-tube assay
for rapid genotyping of the two mutations C282Y
and H63D of the HFE gene, commonly detected by
PCR-RFLP and responsible for 80% of cases of
hereditary hemochromatosis. The method, named
T melting curve analysis, discriminates between
amplification products by their melting tempera-
tures.
Sir,
The eight hemochromatosis (HH) patients in this
study included: two homozygotes for C282Y, two
homozygotes for H63D, two compound heterozy-
gotes and two heterozygotes for C282Y. Four healthy
individuals, two heterozygotes for H63D and two
without HFE mutations, were also studied.
DNA was isolated from peripheral whole blood
using standard protocols. The HFE genotyping was
performed by PCR-RFLP using the procedure
described by Bacon et al.1
The melting temperature assay is based on the abil-
ity to distinguish between PCR amplification prod-
ucts by their melting temperature (Tm).2 The single
tube fluorescent PCR assay uses a specific primer set,
with a high annealing temperature, and the SYBR
green I fluorescent dye, able to detect double strand-
ed DNA products. The temperature at which dou-
ble-strand templates dissociate depends on the prod-
uct length, GC content and sequence structure. The
scientific correspondence
Figure 1.  Melting profile of the wild type (A), mutated (B)
and heterozygous (C) genotypes at position 63 of HFE gene.
On the X axis there are the temperatures at which fluores-
cent data was collected (see materials and methods), the
Y-axis shows the first derivative of the above data. The ver-
tical bold bar highlights the melting point at which the
amplicons reassociate. PCR has been optimized in order to
better discriminate the different genotypes. A good Tm pro-
file is represented in panel B because of low presence of
primer dimers, still present in panels A and C, as the lower
peak which is indicated by arrows. Nevertheless, even the
heterozygous (C) and the wild type (A) are easily distin-
guishable from the primer dimer product.
